Nuo Therapeutics, Inc. Stock

Equities

AURX

US67059V2097

Biotechnology & Medical Research

Delayed OTC Markets 09:51:14 2024-05-15 am EDT 5-day change 1st Jan Change
0.75 USD 0.00% Intraday chart for Nuo Therapeutics, Inc. -6.25% +36.36%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2022 112K Sales 2023 609K Capitalization 24.33M
Net income 2022 -3M Net income 2023 -3M EV / Sales 2022 543 x
Net cash position 2022 1.72M Net cash position 2023 673K EV / Sales 2023 38.9 x
P/E ratio 2022
-18.9 x
P/E ratio 2023
-7.3 x
Employees 9
Yield 2022 *
-
Yield 2023
-
Free-Float 40.7%
More Fundamentals * Assessed data
Dynamic Chart
1 week-6.25%
Current month-6.25%
1 month-21.05%
3 months+22.95%
6 months+25.00%
Current year+36.36%
More quotes
1 week
0.75
Extreme 0.75
0.75
1 month
0.75
Extreme 0.75
0.85
Current year
0.48
Extreme 0.48
0.98
1 year
0.40
Extreme 0.401
1.75
3 years
0.00
Extreme 0.0001
4.50
5 years
0.00
Extreme 0.0001
4.50
10 years
0.00
Extreme 0.0001
4.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 08-09-18
Chief Operating Officer 58 08-08-31
Members of the board TitleAgeSince
Director/Board Member 67 09-01-29
Chief Executive Officer 61 08-09-18
Director/Board Member 75 17-04-06
More insiders
Date Price Change Volume
24-05-15 0.75 0.00% 1,000
24-05-14 0.75 -6.25% 1,000
24-05-08 0.8 +0.13% 6,384

Delayed Quote OTC Markets, May 15, 2024 at 09:51 am EDT

More quotes
Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient's own platelets and plasma as a catalyst for healing. Its commercial offering consists of point of care technology for the separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix or the Aurix System. The Aurix System produces a platelet rich plasma (PRP) gel at the point of care using the patient's own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW